Literature DB >> 12937014

Chemotherapeutic potential of orally administered poly(lactide-co-glycolide) microparticles containing isoniazid, rifampin, and pyrazinamide against experimental tuberculosis.

Qurrat Ul-Ain1, Sadhna Sharma, G K Khuller.   

Abstract

Poly(lactide-co-glycolide) (PLG) microspheres (diameter, less than 3 microm) containing isoniazid, rifampin, and pyrazinamide were used in a sustained oral drug delivery system to treat murine tuberculosis. Drug levels above the MIC were observed up to 72 h in plasma and for 9 days in various organs. Relative bioavailability of encapsulated drugs was greater than that of free drugs. Chemotherapy results showed better or equivalent clearance of bacilli in the PLG-drug-administered group (weekly) than with free drugs (daily).

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12937014      PMCID： PMC182631          DOI： 10.1128/AAC.47.9.3005-3007.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  Gliadin nanoparticles as carriers for the oral administration of lipophilic drugs. Relationships between bioadhesion and pharmacokinetics.

Authors:  M A Arangoa; M A Campanero; M J Renedo; G Ponchel; J M Irache
Journal:  Pharm Res       Date:  2001-11       Impact factor: 4.200

2.  Treatment of tuberculosis using a combination of sustained-release rifampin-loaded microspheres and oral dosing with isoniazid.

Authors:  D C Quenelle; G A Winchester; J K Staas; E L Barrow; W W Barrow
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

3.  Large porous particles for pulmonary drug delivery.

Authors:  D A Edwards; J Hanes; G Caponetti; J Hrkach; A Ben-Jebria; M L Eskew; J Mintzes; D Deaver; N Lotan; R Langer
Journal:  Science       Date:  1997-06-20       Impact factor: 47.728

4.  Sustained release of isoniazid from a single injectable dose of poly (DL-lactide-co-glycolide) microparticles as a therapeutic approach towards tuberculosis.

Authors:  M Dutt; G K Khuller
Journal:  Int J Antimicrob Agents       Date:  2001-02       Impact factor: 5.283

5.  Maintenance of therapeutically active levels of isoniazid for prolonged periods in rabbits after a single implant of biodegradable polymer.

Authors:  S Kailasam; D Daneluzzi; P R Gangadharam
Journal:  Tuber Lung Dis       Date:  1994-10

6.  Methods for the estimation of pyrazinamide and pyrazinoic acid in body fluids.

Authors:  P Gurumurthy; N G Nair; G R Sarma
Journal:  Indian J Med Res       Date:  1980-01       Impact factor: 2.375

7.  Fluorometric determination of isonicotinic acid hydrazide in serum.

Authors:  E M Scott; R C Wright
Journal:  J Lab Clin Med       Date:  1967-08

8.  Chemotherapy of Mycobacterium tuberculosis infections in mice with a combination of isoniazid and rifampicin entrapped in Poly (DL-lactide-co-glycolide) microparticles.

Authors:  M Dutt; G K Khuller
Journal:  J Antimicrob Chemother       Date:  2001-06       Impact factor: 5.790

9.  Therapeutic efficacy of Poly(DL-lactide-Co-Glycolide)-encapsulated antitubercular drugs against Mycobacterium tuberculosis infection induced in mice.

Authors:  M Dutt; G K Khuller
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

10.  Therapeutic efficacy of liposome-entrapped rifampin against Mycobacterium avium complex infection induced in mice.

Authors:  H Saito; H Tomioka
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191
  10 in total
  2 in total

1.  3D Multi-agent models for protein release from PLGA spherical particles with complex inner morphologies.

Authors:  Ana Barat; Heather J Ruskin; Martin Crane
Journal:  Theory Biosci       Date:  2008-04-26       Impact factor: 1.919

2.  Preparation and evaluation of gelatin/sodium carboxymethyl cellulose polyelectrolyte complex microparticles for controlled delivery of isoniazid.

Authors:  Nirmala Devi; Tarun Kumar Maji
Journal:  AAPS PharmSciTech       Date:  2009-11-24       Impact factor: 3.246
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.